WO2002066672A3 - Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists - Google Patents

Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists Download PDF

Info

Publication number
WO2002066672A3
WO2002066672A3 PCT/IB2002/001262 IB0201262W WO02066672A3 WO 2002066672 A3 WO2002066672 A3 WO 2002066672A3 IB 0201262 W IB0201262 W IB 0201262W WO 02066672 A3 WO02066672 A3 WO 02066672A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxidase
antagonists
amino acid
cns disorders
treatment
Prior art date
Application number
PCT/IB2002/001262
Other languages
French (fr)
Other versions
WO2002066672A2 (en
Inventor
Daniel Cohen
Ilya Chumakov
Original Assignee
Genset Sa
Daniel Cohen
Ilya Chumakov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa, Daniel Cohen, Ilya Chumakov filed Critical Genset Sa
Priority to IL15686502A priority Critical patent/IL156865A0/en
Priority to EA200300807A priority patent/EA006654B1/en
Priority to MXPA03006321A priority patent/MXPA03006321A/en
Priority to AU2002247939A priority patent/AU2002247939B2/en
Priority to EP02717019A priority patent/EP1412515A2/en
Priority to CA002433866A priority patent/CA2433866A1/en
Priority to JP2002566376A priority patent/JP2004537275A/en
Priority to KR10-2003-7009412A priority patent/KR20030066813A/en
Priority to BR0206495-2A priority patent/BR0206495A/en
Publication of WO2002066672A2 publication Critical patent/WO2002066672A2/en
Publication of WO2002066672A3 publication Critical patent/WO2002066672A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)

Abstract

Compounds that are antagonists of D-amino acid oxidase and D-aspartate oxidase, methods of treating CNS disorders including bipolar disorder, psychosis and schizophrenia using the compounds, and pharmaceutically acceptable compositions that contain the antagonists are disclosed.
PCT/IB2002/001262 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists WO2002066672A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL15686502A IL156865A0 (en) 2001-01-16 2002-01-15 D-amino acid oxidase and d-aspartate oxidase for use in cns disorders
EA200300807A EA006654B1 (en) 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
MXPA03006321A MXPA03006321A (en) 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists.
AU2002247939A AU2002247939B2 (en) 2001-01-16 2002-01-15 Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
EP02717019A EP1412515A2 (en) 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
CA002433866A CA2433866A1 (en) 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
JP2002566376A JP2004537275A (en) 2001-01-16 2002-01-15 Treatment of CNS disorders using antagonists of D-amino acid oxidase and D-aspartate oxidase
KR10-2003-7009412A KR20030066813A (en) 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
BR0206495-2A BR0206495A (en) 2001-01-16 2002-01-15 Treatment of dog disorders employing d-amino acid oxidase antagonists and d-aspartate oxidase

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26188301P 2001-01-16 2001-01-16
US60/261,883 2001-01-16
US30544501P 2001-07-13 2001-07-13
US60/305,445 2001-07-13
US34521101P 2001-10-22 2001-10-22
US60/345,211 2001-10-22
US33388101P 2001-11-19 2001-11-19
US60/333,881 2001-11-19

Publications (2)

Publication Number Publication Date
WO2002066672A2 WO2002066672A2 (en) 2002-08-29
WO2002066672A3 true WO2002066672A3 (en) 2004-02-26

Family

ID=27500728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/001262 WO2002066672A2 (en) 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists

Country Status (11)

Country Link
EP (1) EP1412515A2 (en)
JP (1) JP2004537275A (en)
KR (1) KR20030066813A (en)
CN (1) CN1568370A (en)
AU (1) AU2002247939B2 (en)
BR (1) BR0206495A (en)
CA (1) CA2433866A1 (en)
EA (1) EA006654B1 (en)
IL (1) IL156865A0 (en)
MX (1) MXPA03006321A (en)
WO (1) WO2002066672A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900218B2 (en) 2001-05-03 2005-05-31 Galileo Pharmaceuticals, Inc. Pyruvate derivatives
WO2003070743A1 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
CA2469923A1 (en) * 2001-12-12 2003-06-19 Genset S.A. Biallelic markers of d-amino acid oxidase and uses thereof
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
CZ2006427A3 (en) 2003-12-29 2006-11-15 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
DK1981862T3 (en) * 2006-01-09 2011-06-14 Oklahoma Med Res Found Lanthionine-related compounds for the treatment of inflammatory diseases
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
GB2456390A (en) * 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
CA3037010A1 (en) 2009-01-20 2010-07-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
JP4462382B1 (en) * 2009-04-23 2010-05-12 学校法人北里研究所 Novel inhibitors for D-aspartate oxidase and D-amino acid oxidase
WO2012135119A1 (en) * 2011-03-25 2012-10-04 Genomind, Llc Biomarker-based detection and treatment of neurodegenerative depression
JP6492003B2 (en) 2012-03-30 2019-03-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ Methods of modulating tau expression to reduce stroke and to modify neurodegenerative syndrome
KR102338171B1 (en) 2016-06-13 2021-12-09 신유알엑스 인터내셔널 (타이완) 코포레이션 Lithium benzoate co-crystals and uses thereof
CN109563018A (en) 2016-06-13 2019-04-02 心悦生医股份有限公司 Eutectic of sodium benzoate and application thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
CN108504752B (en) * 2018-06-26 2021-05-11 华中农业大学 Molecular marker associated with sow breeding traits and application
CN111909907B (en) * 2020-07-08 2022-05-24 浙江工业大学 Aspartate oxidase mutant, engineering bacteria and application of aspartate oxidase mutant in preparation of refined glufosinate-ammonium through oxidation-reduction coupling

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology
WO2000058510A2 (en) * 1999-03-30 2000-10-05 Genset Schizophrenia associated genes, proteins and biallelic markers
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology
WO2000058510A2 (en) * 1999-03-30 2000-10-05 Genset Schizophrenia associated genes, proteins and biallelic markers
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHORK N J ET AL: "SINGLE NUCLEOTIDE POLYMORPHISM AND THE FUTURE OF GENETIC EPIDEMIOLOGY", CLINICAL GENETICS, COPENHAGEN, DK, vol. 58, 2000, pages 250 - 264, XP000985433 *

Also Published As

Publication number Publication date
CA2433866A1 (en) 2002-08-29
AU2002247939B2 (en) 2007-01-25
IL156865A0 (en) 2004-02-08
EA006654B1 (en) 2006-02-24
CN1568370A (en) 2005-01-19
EA200300807A1 (en) 2004-08-26
MXPA03006321A (en) 2003-10-06
BR0206495A (en) 2006-01-24
AU2002247939B9 (en) 2002-09-04
KR20030066813A (en) 2003-08-09
JP2004537275A (en) 2004-12-16
WO2002066672A2 (en) 2002-08-29
EP1412515A2 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
WO2002066672A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
WO2004054501A3 (en) Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
WO2004021989A3 (en) Imidazolopyridines and methods of making and using the same
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
PL368973A1 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2002041889A3 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
WO2003087304A3 (en) Tri-substituted heteroaryls and methods of making and using the same
WO2003047558A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
WO2000035919A3 (en) Quinoline derivatives
WO2003082208A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2002064594A3 (en) 6-substituted pyrido-pyrimidines
WO2004009559A3 (en) Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
AU2002352832A1 (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2001098279A3 (en) Bis-arylsulfones
WO2003045330A3 (en) Materials and methods for making improved micelle compositions
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
WO2002073208A3 (en) Anti-epileptogenic agents
GB0322510D0 (en) Novel compounds
WO2002024695A3 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
WO2004032908A3 (en) Method of inhibiting angiogenesis
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2000047547A3 (en) Cycloalkyl amine compounds and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2433866

Country of ref document: CA

Ref document number: 2002247939

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 156865

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002717019

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006321

Country of ref document: MX

Ref document number: 1020037009412

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002566376

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1020037009412

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200300807

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 028066650

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002717019

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0206495

Country of ref document: BR